Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Curr Comput Aided Drug Des ; 16(5): 541-554, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31749432

RESUMO

INTRODUCTION: The enzyme Glycogen Synthase Kinase 3-ß (GSK-3ß) is related to neuronal cell degeneration, representing a promising target to treat Alzheimer's Disease (AD). METHODS: In this work, we performed a molecular modeling study of existing GSK-3ß inhibitors by means of evaluation of their IC50 values, derivation of a pharmacophore model, molecular docking simulations, ADME/Tox properties predictions, molecular modifications and prediction of synthetic viability. RESULTS: In this manner, inhibitor 15 (CID 57399952) was elected a template molecule, since it demonstrated to bear relevant structural groups able to interact with GSK-3ß, and also presented favorable ADME/Tox predicted properties, except for mutagenicity. Based on this inhibitor chemical structure we proposed six analogues that presented the absence of alerts for mutagenic and carcinogenic activity, both for rats and mouse; likewise they all presented low risk alerts for inhibition of hERG and medium prediction of synthetic viability. CONCLUSION: It is concluded that the analogues of GSK-3ß inhibitors were optimized in relation to the toxicity endpoint of the template molecule, being, therefore, presented as novel and promising drug candidates for AD treatment.


Assuntos
Inibidores Enzimáticos/química , Inibidores Enzimáticos/farmacologia , Glicogênio Sintase Quinase 3 beta/antagonistas & inibidores , Simulação de Acoplamento Molecular , Doença de Alzheimer/tratamento farmacológico , Concentração Inibidora 50
2.
ChemMedChem ; 12(16): 1408-1416, 2017 08 22.
Artigo em Inglês | MEDLINE | ID: mdl-28417566

RESUMO

Cannabis sativa withdrawal syndrome is characterized mainly by psychological symptoms. By using computational tools, the aim of this study was to propose drug candidates for treating withdrawal syndrome based on the natural ligands of the cannabinoid type 1 receptor (CB1). One compound in particular, 2-n-butyl-5-n-pentylbenzene-1,3-diol (ZINC1730183, also known as stemphol), showed positive predictions as a human CB1 ligand and for facile synthetic accessibility. Therefore, ZINC1730183 is a favorable candidate scaffold for further research into pharmacotherapeutic alternatives to treat C. sativa withdrawal syndrome.


Assuntos
Cannabis/química , Ligantes , Receptor CB1 de Canabinoide/metabolismo , Animais , Barreira Hematoencefálica/efeitos dos fármacos , Barreira Hematoencefálica/metabolismo , Células CACO-2 , Cannabis/metabolismo , Permeabilidade da Membrana Celular/efeitos dos fármacos , Desenho de Fármacos , Meia-Vida , Humanos , Camundongos , Receptor CB1 de Canabinoide/agonistas , Receptor CB2 de Canabinoide/agonistas , Receptor CB2 de Canabinoide/metabolismo , Resorcinóis/química , Resorcinóis/farmacocinética , Resorcinóis/farmacologia , Resorcinóis/uso terapêutico , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Síndrome de Abstinência a Substâncias/metabolismo , Síndrome de Abstinência a Substâncias/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...